menu
    • menu
    [{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"powder for solution for infusion","sponsorNew":"Medac \/ Medexus Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Medexus Pharma"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Treosulphan

    Menu

    Treosulphan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update

                            Details : Trecondyv (treosulfan) is used to prepare patients for blood stem cell transplant. Trecondyv destroys bone marrow cells. This allows for the transplant of new blood stem cells from a donor which leads to the production of healthy blood cells.

                            Brand Name : Trecondyv

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 19, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Medac

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Treosulfan Pivotal Study Results Published

                            Details : Study found event-free survival and overall survival superior after Trecondyv (treosulfan) compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm.

                            Brand Name : Trecondyv

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Medac

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

                            Details : Trecondyv (treosulfan), preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, is medication given to people before they have bone marrow transplant from a donor allogeneic hematopoietic ste...

                            Brand Name : Trecondyv

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

                            Details : The resubmission includes additional clinical data and statistical analysis relating to previously-completed phase 3 clinical trial of Treosulfan as well as an update of integrated summary of safety, which FDA had requested in their July 2021 Complete Re...

                            Brand Name : Treosulfan

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medac

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Medac

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, T...

                            Details : Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (“allo-HSCT”).

                            Brand Name : Trecondyv

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2021

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medac

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Medac

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus and Medac Enter Into a License Agreement for Treosulfan, in the United States

                            Details : Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.

                            Brand Name : Trecondi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 02, 2021

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth